In the News

Ikena Oncology's IK-930 Trial Discontinued

Ikena Oncology IK-930 Update

By The EHE Foundation / June 7, 2024 / 0 Comments

On May 28, 2024, Ikena Oncology announced they are discontinuing the development of IK-930. We share your frustration and disappointment and understand the devastating impact felt by patients. Following this announcement, we met with Ikena to impress upon them the urgency and importance that patients deriving benefits from IK-930 continue to have access to the […]

Read More
EHE Advocates at the ESMO Congress 2024

EHE Advocates at the ESMO Sarcoma and Rare Cancers Congress 2024

By The EHE Foundation / March 29, 2024 / Comments Off on EHE Advocates at the ESMO Sarcoma and Rare Cancers Congress 2024

In March Denise Robinson, Director of Research for The EHE Foundation attended the ESMO Sarcoma and Rare Cancers Congres 2024 in Lugano, Switzerland. This congress brought together world-renowned experts including researchers and clinicians, to present and discuss the latest advancements in the treatment of sarcomas and rare cancers.  Topics ranged from the role of immune […]

Read More
PUSH Project: Pushing Rare Sarcoma Beyond Hope

PUSH Project: Pushing Rare Sarcoma Beyond Hope

By The EHE Foundation / March 29, 2024 / Comments Off on PUSH Project: Pushing Rare Sarcoma Beyond Hope

Under the umbrella of the Connective Tissue Oncology Society (CTOS), the Ultra-rare Sarcoma Working Group, a broad group representing the global sarcoma community, including clinicians, scientists, patient advocates, and non-profit organizations has come together to establish a consortium, PUSH, to collect and make the best use of all available evidence to facilitate the development of […]

Read More
Science Saturday: Patient-Powered EHE Research

Science Saturday: Patient-Powered EHE Research

By The EHE Foundation / March 13, 2024 / Comments Off on Science Saturday: Patient-Powered EHE Research

On Saturday, February 24, 2024, Denise Robinson, Director of Research provided an update to the global EHE community focused on ‘Patient-Powered EHE Research’. Denise highlighted research projects The EHE Foundation is funding and supporting through resources, and projects initiated by the foundation including the EHE Global Patient Registry and EHE Biobank. Denise highlights progress made […]

Read More
IK-930 Orphan Drug Designation

IK-930 Receives Orphan Drug Designation for EHE

By The EHE Foundation / January 10, 2024 / Comments Off on IK-930 Receives Orphan Drug Designation for EHE

Ikena Oncology has shared that on December 14th, 2023, the Food and Drug Administration (FDA) granted Orphan Drug Designation to IK-930 for the treatment of epithelioid hemangioendothelioma (EHE). We are excited about this designation following initial positive data from the IK-930 Phase I clinical trial published in Ikena’s November 9th press release. What does this […]

Read More
John McFadden joins The EHE Foundation Board of Directors.

Welcome New Board Member John McFadden, Ph.D., CRNA, APRN

By The EHE Foundation / November 17, 2023 / Comments Off on Welcome New Board Member John McFadden, Ph.D., CRNA, APRN

The EHE Foundation was founded by patients, for patients. Continuing that tradition, we aredelighted to announce that EHE patient John McFadden, Ph.D., CRNA, APRN, has joined ourBoard of Directors. With more than 35 years of experience in health care, Dr. McFadden has held positions as anurse executive, hospital and university program accreditation surveyor, faculty member, […]

Read More